Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
10.52
-0.60 (-5.40%)
Oct 21, 2024, 4:00 PM EDT - Market closed
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
58
Market Cap
347.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
Dec 31, 2021 | 1.66M | 1.14M | 219.59% |
Dec 31, 2020 | 518.48K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLXEO News
- 6 weeks ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 3 months ago - Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further - Seeking Alpha
- 3 months ago - Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet - Benzinga
- 3 months ago - Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - GlobeNewsWire
- 3 months ago - Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors - GlobeNewsWire
- 5 months ago - Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 6 months ago - Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - GlobeNewsWire